Semiannual Report — FY2026 H1
What KYORIN Pharmaceutical Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31.
During the interim consolidated accounting period, revenue declined year on year and selling, general and administrative expenses decreased as a reaction to the previous period, while the company recognized a loss on the transfer of the generic pharmaceuticals business under the agreement dated 30 September 2026 as an extraordinary loss. As a result, the company reported an interim net loss attributable to owners of the parent of ¥1,566 million. In addition, the filing discloses the execution of an agreement for the succession of the generic pharmaceuticals business (scheduled succession date: 1 April 2027), as well as agreements for the acquisition of exclusive rights and distribution of EB05, DAYBUE STIX and other products.
Komori's summary of this document, not the document's own words.